The intensive group achieved HbA1c levels of 7 % on an average compared with 8.3 % among more than 25,000 patients from 67 US centres in the T1D exchange [59], and this was achieved without modern advances in therapy, such as insulin analogues and continuous glucose monitors. The gene discussed is INS; the disease is type 1 diabetes mellitus.